- Home
- BTGO vs OMER Comparison
BTGO vs OMER Comparison
Compare BTGO & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTGO | OMER |
|---|---|---|
| Founded | 2013 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 806.4M | 844.6M |
| IPO Year | 2025 | 2008 |
Fundamental Metrics
Financial Performance| Metric | BTGO | OMER |
|---|---|---|
| Price | $6.95 | $18.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $14.83 | ★ $32.50 |
| AVG Volume (30 Days) | 1.7M | ★ 2.3M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $34.41 | $233.22 |
| P/E Ratio | ★ $10.81 | $24.35 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.65 | $3.94 |
| 52 Week High | $15.30 | $19.65 |
Technical Indicators
Market Signals| Indicator | BTGO | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 63.09 | 72.16 |
| Support Level | $4.70 | $9.12 |
| Resistance Level | $12.11 | $19.65 |
| Average True Range (ATR) | 0.46 | 0.87 |
| MACD | 0.07 | -0.08 |
| Stochastic Oscillator | 75.82 | 83.29 |
Price Performance
Historical ComparisonAbout BTGO BitGo Holdings Inc. Class A Common Stock
BitGo Holdings Inc provides various offerings to its clients including multi-signature blockchain wallet solutions allowing for secure storage, trade settlement, staking solutions, and lending of digital assets. The Company also provides professional services to develop smart contracts. Its clients range from crypto-native companies that use its self-custody wallet technology to traditional financial services firms that leverage its licensed custody, staking and trading capabilities within their own products and services.
About OMER Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.